NASDAQ:ETON Eton Pharmaceuticals (ETON) Stock Price, News & Analysis $36.01 -1.32 (-3.54%) As of 11:49 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Eton Pharmaceuticals Stock (NASDAQ:ETON) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Eton Pharmaceuticals alerts:Sign Up Key Stats Today's Range$35.22▼$37.3050-Day Range$23.58▼$38.0252-Week Range$13.76▼$38.62Volume89,005 shsAverage Volume368,842 shsMarket Capitalization$986.31 millionP/E RatioN/ADividend YieldN/APrice Target$41.00Consensus RatingHold Company Overview Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings. The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis. Eton gained U.S. Food and Drug Administration approval for several abbreviated new drug applications (ANDAs) and new drug applications (NDAs), enabling it to bring both generic and specialty branded medicines to market. Its development pipeline features additional hormone replacement therapies and other complex dosage forms intended to broaden its reach in endocrine and rare disease markets. Eton Pharmaceuticals serves patients and healthcare providers across the United States through strategic partnerships with wholesalers, specialty pharmacies and healthcare institutions. The company employs a network of contract manufacturing organizations to ensure product quality and supply chain efficiency. With a focus on regulatory compliance, timely product launches and niche market development, Eton continues to pursue opportunities that align with its mission of improving care for patients with limited treatment options.AI Generated. May Contain Errors. Read More Eton Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks45th Percentile Overall ScoreETON MarketRank™: Eton Pharmaceuticals scored higher than 45% of companies evaluated by MarketBeat, and ranked 504th out of 849 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.9 / 5Analyst RatingHold Consensus RatingEton Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialEton Pharmaceuticals has a consensus price target of $41.00, representing about 13.9% upside from its current price of $36.00.Amount of Analyst CoverageEton Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Eton Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth154.67% Earnings GrowthEarnings for Eton Pharmaceuticals are expected to grow by 154.67% in the coming year, from $0.75 to $1.91 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Eton Pharmaceuticals is -514.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Eton Pharmaceuticals is -514.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEton Pharmaceuticals has a P/B Ratio of 36.73. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Eton Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.23% of the float of Eton Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEton Pharmaceuticals has a short interest ratio ("days to cover") of 4.13.Change versus previous monthShort interest in Eton Pharmaceuticals has recently increased by 13.04%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEton Pharmaceuticals does not currently pay a dividend.Dividend GrowthEton Pharmaceuticals does not have a long track record of dividend growth. News and Social Media1.3 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Eton Pharmaceuticals this week, compared to 3 articles on an average week.Search Interest10 people have searched for ETON on MarketBeat in the last 30 days. This is an increase of 11% compared to the previous 30 days.MarketBeat Follows6 people have added Eton Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Eton Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,853,921.00 in company stock.Percentage Held by Insiders16.49% of the stock of Eton Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions27.86% of the stock of Eton Pharmaceuticals is held by institutions.Read more about Eton Pharmaceuticals' insider trading history. Receive ETON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eton Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ETON Stock News HeadlinesAnalysts Offer Insights on Healthcare Companies: Eton Pharmaceuticals (ETON), Tarsus Pharmaceuticals (TARS) and Arrowhead Pharmaceuticals (ARWR)July 7 at 1:41 PM | theglobeandmail.comEton Pharmaceuticals (NASDAQ:ETON) Director Jennifer Mckie Adams Sells 50,000 SharesJune 18, 2026 | insidertrades.comIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of the world's oil passing through that corridor, crude has already crossed $100 per barrel. History shows gold surged 571% during the 1973 oil crisis and 425% in 1979. Today, the U.S. holds 8,133 tonnes of gold valued on the books at $42.22 per ounce - while gold trades above $5,000. American Alternative Assets has released The Great Gold Reset report detailing what this gap could mean for investors.July 10 at 1:00 AM | American Alternative (Ad)Eton Shareholders Back Board Nominees and Auditor SelectionJune 9, 2026 | tipranks.comEton Pharmaceuticals Inc (ETON) Shares Fall 4.3% -- What GF Score of 70 Tells InvestorsMay 29, 2026 | gurufocus.comH.C. Wainwright Remains Bullish on Eton Pharmaceuticals’ (ETON) Growth StrategyMay 23, 2026 | finance.yahoo.comEton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)May 19, 2026 | globenewswire.comEton Pharmaceuticals, Inc. Just Missed EPS By 44%: Here's What Analysts Think Will Happen NextMay 16, 2026 | finance.yahoo.comSee More Headlines ETON Stock Analysis - Frequently Asked Questions How have ETON shares performed this year? Eton Pharmaceuticals' stock was trading at $16.91 at the beginning of 2026. Since then, ETON stock has increased by 112.9% and is now trading at $35.9950. How were Eton Pharmaceuticals' earnings last quarter? Eton Pharmaceuticals, Inc. (NASDAQ:ETON) released its earnings results on Thursday, May, 14th. The company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.10 by $0.05. The firm had revenue of $24.27 million for the quarter, compared to the consensus estimate of $22.31 million. Eton Pharmaceuticals had a negative trailing twelve-month return on equity of 5.68% and a negative net margin of 1.70%. Read the conference call transcript. When did Eton Pharmaceuticals IPO? Eton Pharmaceuticals (ETON) raised $22 million in an initial public offering (IPO) on Wednesday, November 14th 2018. The company issued 3,600,000 shares at $6.00 per share. National Securities Corporation acted as the underwriter for the IPO. Who are Eton Pharmaceuticals' major shareholders? Eton Pharmaceuticals' top institutional shareholders include Wasatch Advisors LP (0.34%). Insiders that own company stock include Opaleye Management Inc, James R Gruber, Jennifer Mckie Adams and David Krempa. View institutional ownership trends. How do I buy shares of Eton Pharmaceuticals? Shares of ETON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Eton Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Eton Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Arista Networks (ANET), CrowdStrike (CRWD) and Advanced Micro Devices (AMD). Company Calendar Last Earnings5/14/2026Today7/10/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 ETON's financial health is in the Green zone, according to TradeSmith. ETON has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ETON CIK1710340 Webwww.etonpharma.com Phone(847) 787-7361FaxN/AEmployees20Year Founded2017Price Target and Rating Average Price Target for Eton Pharmaceuticals$41.00 High Price Target$57.00 Low Price Target$31.00 Potential Upside/Downside+14.5%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.07) Trailing P/E RatioN/A Forward P/E Ratio47.74 P/E GrowthN/ANet Income-$4.60 million Net Margins-1.70% Pretax Margin-1.71% Return on Equity-5.68% Return on Assets-1.49% Debt Debt-to-Equity Ratio0.62 Current Ratio1.21 Quick Ratio0.88 Sales & Book Value Annual Sales$79.95 million Price / Sales12.27 Cash Flow$0.01 per share Price / Cash Flow6,978.31 Book Value$0.98 per share Price / Book36.54Miscellaneous Outstanding Shares27,390,000Free Float22,875,000Market Cap$980.75 million OptionableOptionable Beta0.86 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:ETON) was last updated on 7/10/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredExecutive order could send gold to 6,000 per ounceExecutive Order 14330 will allow Americans to hold precious metals inside 401(k)s for the first time ever - an...Cedar Gold Group | SponsoredIs the fix for AI's runaway power problem your golden ticket?The government just committed $200 billion to building computer chips on American soil - one of the largest te...Eagle Publishing | SponsoredThe window is closingWe printed 1,000 copies of this report and 688 are gone—when the last one goes out, we're pulling it offline b...American Alternative | SponsoredJeff Brown and Marc Chaikin's latest AI prediction explainedJeff Brown and Marc Chaikin - the duo who identified Nvidia a decade ago - are forecasting that Elon Musk's AI...Brownstone Research | SponsoredRay Dalio: Buy Gold. Get Paid.Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eton Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eton Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ETON Stock Alerts